Diet Choice Tied To Deadly Cancer Recurrence

Patient arm with IV line in a hospital chair — Photo: goodbishop / Shutterstock

Blood drawn years after a breast cancer survivor rings the bell and walks out of treatment can still carry a warning sign doctors are only now learning to read.

Story Snapshot

A 734-woman study found high inflammation markers measured about three years after treatment linked to roughly double the risk of recurrence and death.
Separate research tied elevated C-reactive protein and serum amyloid A, two blood markers of inflammation, to worse survival in breast cancer patients.
A cytokine called IL-6, measured at diagnosis, predicted higher odds of distant recurrence in HER2-negative early breast cancer.
Scientists stress these findings show association, not proof, that inflammation causes recurrence.

What The Multi-Site Study Actually Found

Researchers tracked 734 women who had been successfully treated for early-stage breast cancer. About three years after treatment ended, those with high levels of circulating acute phase proteins, substances the liver releases during inflammation, faced roughly twice the risk of their cancer returning or of dying, compared to women with lower levels. That is a striking number for women who thought the hardest part was behind them.

The same body of research zeroed in on two specific markers, C-reactive protein and serum amyloid A. A published summary described systemic inflammation, measured through these two proteins, as a potentially important long-term signal for how breast cancer patients fare over time. These aren’t exotic lab tests. C-reactive protein shows up on routine blood panels used for heart disease and other conditions, which makes it an appealing, low-cost tool if its link to cancer recurrence holds up under further study.

The WHEL Study Adds Years Of Follow-Up Data

The Women’s Healthy Eating and Living Study followed breast cancer patients for a median of 7.4 years and recorded 417 additional breast cancer events, including recurrences, during that stretch. Researchers found that C-reactive protein levels measured after diagnosis were tied to death from any cause, death from breast cancer specifically, and new breast cancer events. Women with the highest readings, at or above 10 milligrams per liter, faced close to double the risk of dying compared to those with the lowest levels.

A separate analysis of the Wellness After Breast Cancer-II cohort narrowed the picture further. Among women with hormone receptor-positive, HER2-negative disease, both C-reactive protein and serum amyloid A were significantly tied to higher recurrence risk. The same pattern did not hold for women whose tumors were also HER2-positive. That split matters because it suggests inflammation’s warning signal may not apply evenly across every type of breast cancer.

A Different Marker Points To The Same Danger

Diagnosis-stage blood work told a similar story through a different lens. A study published in npj Breast Cancer measured inflammatory cytokines in women with HER2-negative early breast cancer and found that interleukin-6, a protein the immune system releases during inflammation, was the one biomarker significantly tied to distant recurrence after accounting for multiple comparisons. The increased risk, about 37 percent, was smaller than the near-doubling seen with acute phase proteins, a reminder that not every inflammation marker carries equal weight.

Diet And Lifestyle Enter The Picture

Blood tests are not the only way researchers have measured inflammation’s footprint. A study of 511 women tracked a dietary inflammatory index after surgery, essentially scoring how pro-inflammatory a patient’s eating habits were. Women eating more inflammatory diets faced over twice the risk of recurrence and three times the risk of death compared to those eating anti-inflammatory diets. That finding opens a door survivors can actually walk through, since diet is something patients can change, unlike a genetic marker fixed at birth.

None of these studies prove that inflammation itself drives cancer back. The language throughout this research leans on words like “associated with” and “linked to,” not “causes.” Inflammation markers also rise with obesity, chronic illness, and even the side effects of cancer treatment itself, so a high reading might reflect overall poor health rather than a direct pipeline to recurrence. Separating the signal from the noise will take more work.